SIS17

SIS17 is a potent and selective small molecule inhibitor of histone deacetylase 11 (HDAC11), with an IC50 value of 0.83 μM. It inhibits the demyristoylation activity of HDAC11 on substrates such as serine hydroxymethyltransferase 2, without affecting other HDAC isoforms. Developed initially by Cornell University, SIS17 demonstrates good cell permeability and metabolic stability compared to other HDAC11 inhibitors. Its primary research applications are in the fields of immunology, infectious diseases, nervous system diseases, and metabolic disorders. Preclinical studies suggest potential utility in modulating neuroinflammation and immune responses; however, it has not advanced beyond preclinical development due to limitations related to selectivity or pharmacokinetics[1][3][4][6][9].